Research Papers:

Metabolic syndrome in relation to risk of meningioma

Corinna Seliger _, Christoph R. Meier, Claudia Becker, Susan S. Jick, Martin Proescholdt, Ulrich Bogdahn, Peter Hau and Michael F. Leitzmann

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:2284-2292. https://doi.org/10.18632/oncotarget.13667

Metrics: PDF 1743 views  |   HTML 2686 views  |   ?  


Corinna Seliger1, Christoph R. Meier2,3,4, Claudia Becker2, Susan S. Jick3, Martin Proescholdt5, Ulrich Bogdahn1, Peter Hau1, Michael F. Leitzmann6

1Department of Neurology and Wilhelm Sander-NeuroOncology Unit, Regensburg University Hospital, Regensburg, Germany

2Basel Pharmacoepidemiology Unit, Division of CIinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland

3Boston Collaborative Drug Surveillance Program, Boston University School of Public Health, Boston University, MA, USA

4Hospital Pharmacy, University Hospital Basel, Basel, Switzerland

5Department of Neurosurgery, Regensburg University Hospital, Regensburg, Germany

6Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany

Correspondence to:

Corinna Seliger, email: [email protected]

Keywords: meningioma, epidemiology, case-control study, metabolic syndrome

Received: August 27, 2016     Accepted: November 21, 2016     Published: November 26, 2016


Background: Meningioma is a frequent primary intracranial tumor, the etiology of which is potentially related to adiposity. Metabolic syndrome (MetS) is an increasingly common disease characterized by having at least three of the following conditions: central adiposity, arterial hypertension, dyslipidemia, and insulin resistance. Only one prior study investigated MetS in relation to meningioma risk and found a positive association between the two.

Results: Among 2,027 cases and 20,269 controls, body mass index was positively associated with meningioma (p-value for trend < 0.0001). Arterial hypertension was also associated with an increased risk of meningioma (OR = 1.34; 95% CI = 1.20– 1.49). By comparison, high-density lipoprotein, triglycerides, fasting serum glucose, and use of ACE-inhibitors, AT-II inhibitors, beta-blockers, diuretics, calcium antagonists, nitrates, or statins were not associated with risk of meningioma.

Materials and Methods: We conducted a matched case-control analysis using data from the U.K.-based Clinical Practice Research Datalink (CPRD) to analyse medical conditions and treatments related to MetS in cases with meningioma and meningioma-free controls. We identified all cases with an incident diagnosis of meningioma between 1995 and 2015 and matched each to ten controls on age, sex, calendar time, general practice, and number of years of active history in the CPRD prior to the index date. Exposures were assessed using computerised records. We conducted conditional logistic regression analysis to determine relative risks, estimated as odds ratios (ORs) with 95% confidence intervals (CIs), adjusted for confounding factors.

Conclusions: Obesity and arterial hypertension are positively associated with risk of meningioma. Further studies are needed to better understand potential underlying biologic mechanisms.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13667